Manhattan Scientifics Schedules Investor Conference Call on Its Affiliate, Imagion Biosystems IPO

NEW YORK–(BUSINESS WIRE)– Manhattan Scientifics Inc. (OTCQB: MHTX) announced today that it will
host a conference call for MHTX investors at 12:00 pm Eastern Time on
Friday, June 16, 2017 to provide an update and briefing on the pending
Imagion Biosystems IPO (IBX). There will not be a Q&A Session and
participants will be restricted to listening mode.

Participants can dial into the call using the following instruction.

USA & Canada: Conference Toll Free Number: 1-800-753-0565

Conference Toll Number: 1-512-879-2025

Participant Access Code: 673031#

Participant Code Command: *0 – to Summon an Operator

A replay of the call will be posted on the company website http://mhtx.com.

Manhattan Scientific’s affiliate company, Imagion Biosystems Limited,
formerly known as Senior Scientific, LLC, has filed a prospectus with
the Australian Securities and Investment Commission and has applied to
the Australian Securities Exchange for an Initial Public Offering
(« IPO ») to raise up to A$12 million at A$0.20 per share. You can read
the Imagion offering prospectus on Imagion’s website: https://imagionbiosystems.com/investor-relations/
“go to prospectus”.

Funds raised in the IPO are expected to be used in Imagion’s efforts to
move to clinical product development followed by human clinical testing.
Assuming the closing of the IPO and the issuance of additional shares to
Manhattan Scientifics from the conversion of a note, Manhattan
Scientifics is projected to own approximately 64.1 million IBX shares
equal to approximately 29.2% of Imagion.

About Manhattan Scientifics, Inc.

Manhattan Scientifics Inc. (www.mhtx.com)
is located in New Mexico, New York and Montreal. It is focused on
technology transfer and commercialization of transformative technologies.

About Imagion Biosystems Limited

Imagion Biosystems Limited (www.imagionbiosystems.com)
is an Australian corporation with underlying business operations largely
focused on research and development of the MagSense™ SPMR technology,
including both the technology employed in the measuring instrument and
various formulations of nanoparticles for detecting specific types of
diseases.

Forward-looking statement

This press release contains forward-looking statements, which are
subject to a number of risks, assumptions and uncertainties that could
cause the Company’s actual results to differ materially from those
projected in such forward-looking statements. Management at Manhattan
Scientifics believes that purchase of its shares should be considered to
be at the high end of the risk spectrum. Forward-looking statements
speak only as of the date made and are not guarantees of future
performance. We undertake no obligation to publicly update or revise any
forward-looking statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170614006136/en/